<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04864509</url>
  </required_header>
  <id_info>
    <org_study_id>2020-AKA</org_study_id>
    <nct_id>NCT04864509</nct_id>
  </id_info>
  <brief_title>The Effects of Melatonin Treatment on Bone, Marrow, Sleep and Blood Pressure</brief_title>
  <official_title>The Effects of Melatonin Treatment on Bone, Marrow, Sleep and Blood Pressure in Post Menopausal Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Melatonin protects your bones while losing fat! This was previously demonstrated by our&#xD;
      group. The mechanisms behind these findings are still elusive, and the aim of the present&#xD;
      study is to assess the mechanisms.&#xD;
&#xD;
      In a double-blinded randomized controlled trial 40 postmenopausal woman are randomized to&#xD;
      receive either 10 mg melatonin or placebo nightly for three months. Changes in gene&#xD;
      expression in marrow cells will be assessed through micro array. Markers of bone metabolism&#xD;
      will be assessed through biochemical markers. Cardiovascular health will be measured by&#xD;
      tonometry and 24h blood pressure.&#xD;
&#xD;
      The results of the study will contribute with important knowledge about the beneficial&#xD;
      effects of melatonin making it an interesting supplement to known treatment regimens against&#xD;
      osteoporosis and overweight.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 1, 2021</start_date>
  <completion_date type="Anticipated">June 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>double blinded</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Gene expression</measure>
    <time_frame>After study completion. Up to one year</time_frame>
    <description>Changes in gene expression in human mesenchymal stem cells.The biopsies are put on freeze after obtaining them. All biopsies are analysed at once.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Biochemical markers</measure>
    <time_frame>After study completion. Up to one year</time_frame>
    <description>Changes in biochemical markers of bone metabolism measured in blood: Markers include PTH (pmol/l), ionized calcium (mmol/l) CTX (ug/l). Although different units they all contribute to the overall evaluation of bone metabolism and must therefore be regarded as the same outcome measure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of sleep</measure>
    <time_frame>After study completion. Up to one year</time_frame>
    <description>Assessed through the questionnaire Pittsburgh quality of sleep questionnaire. A validated questionnaire assessing the quality of sleep. A score between 0-5 indicates a good quality of sleep. Scores above 5 indicate a poor quality of sleep.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular health</measure>
    <time_frame>After study completion. Up to one year</time_frame>
    <description>Changes in 24h blood pressure and arterial stiffness measured by standardized equipment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Osteoporosis, Postmenopausal</condition>
  <arm_group>
    <arm_group_label>Melatonin 10mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nightly oral dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>nightly oral dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melatonin 10 MG</intervention_name>
    <description>Nightly dose</description>
    <arm_group_label>Melatonin 10mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Nightly dose</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Post-menopausal women between 55 and 75 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Severely impaired renal function&#xD;
&#xD;
          -  Severely impaired hepatic function&#xD;
&#xD;
          -  Coagulation factors PP&lt;0.6&#xD;
&#xD;
          -  Hypercalcemia (p-ion calcium &gt;1.32 nmol/l)&#xD;
&#xD;
          -  Previous or present malignancies (except a treated skin cancer that is not melanoma or&#xD;
             treated carcinoma in situ, 2 years since last therapy)&#xD;
&#xD;
          -  Diseases affecting the calcium homeostasis including untreated thyroid diseases&#xD;
&#xD;
          -  Regular use of medicine affecting the calcium homeostasis, including diuretics,&#xD;
             fenemal, lithium, antiepileptica and glucosteroids&#xD;
&#xD;
          -  Selective serotonin reuptake inhibitor (SSRI)-products with fluvoxamin&#xD;
&#xD;
          -  Treatment with carbamazepin&#xD;
&#xD;
          -  Treatment with rifampicin&#xD;
&#xD;
          -  Severe malabsorption syndrome including gastric or intestinal resection&#xD;
&#xD;
          -  Alcohol or drug abuse&#xD;
&#xD;
          -  Smokers&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>self-presentation</gender_description>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne Kristine Amstrup</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aarhus University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anne Kristine Amstrup</last_name>
    <phone>78 45 54 75</phone>
    <email>anneamst@rm.dk</email>
  </overall_contact>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>August 12, 2020</study_first_submitted>
  <study_first_submitted_qc>April 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 29, 2021</study_first_posted>
  <last_update_submitted>April 27, 2021</last_update_submitted>
  <last_update_submitted_qc>April 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Osteoporosis, Postmenopausal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melatonin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

